Silver salts of racemic 2H-perfluoro(3-oxahexanoic) (3a), perfluoro(2-methyl-3-oxahexanoic) (3b) and 2,3,3,3-tetrafluoro-2-methoxypropanoic acid (3c) gave with Hoveyda-Grubbs 2nd generation catalyst 4 or its bis(polyfluoroalkylated) analogue 5 the corresponding bis(polyfluoroacylated) ruthenium complexes 1a–1c or 2a, 2b as mixtures of three diastereoisomers. Their catalytic activity in model ring-closing
Methyl fluoroalkanoate as methyl-transferring reagent. Unexpected participation of BAl2 (SN2) mechanism in the reaction of methyl 2,3,3,3-tetrafluoro-2-methoxypropanoate with amines
In the reaction of methyl 2,3,3,3-tetrafluoro-2-methoxypropanoate with arylamines or arylmethylamines, an unexpected methyl transfer from the ester to the amine by the BAl2 (SN2) mechanism was observed leading to the corresponding N-methylamines under specific conditions. The reaction was accompanied by the formation of amides via BAc2 mechanism. The unexpected methyl transfer is highly dependent on
在2,3,3,3-四氟-2-甲氧基丙酸甲酯与芳基胺或芳基甲基胺的反应中,观察到通过B Al 2(S N 2)机理从酯到胺的意外甲基转移,导致相应的N-甲胺在特定条件下。该反应伴随着通过B Ac 2机理形成酰胺。意外的甲基转移高度依赖于起始胺的结构,并且由于不存在溶剂和高温而得到支持。
Ionically conductive polymeric materials
申请人:Centre National de la Recherche Scientifique
公开号:US05350646A1
公开(公告)日:1994-09-27
The present invention relates to ionically conductive polymeric materials, to their preparation and to their use as a solid electrolyte. The materials comprise a solid solution of one or more salts in a polymer and are characterized in that the transport and the mobility of a metal cation M.sup.n+ which has the valency n, 1.ltoreq.n.ltoreq.5, are provided by at least one complex anion, corresponding to the general formula [MZ.sub.n Y.sub.p ].sup.p- formed between an anionic ligand Z.sup.-, an anionic ligand Y.sup.- and the cation M.sup.n+, with 1.ltoreq.p.ltoreq.3. Application to the formation of electrochemical generators and of electrochemical systems which make it possible to affect the transmission of light.
This invention relates to compounds of the formula
wherein R
1
to R
9
are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE2 inhibitors and can be used as medicaments for the therapeutic and/or prophylactic treatment of diseases such as diabetes, particularly type 2 diabetes, and other metabolic disorders.
This invention relates to compounds of the formula
wherein R1 to R9 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE2 inhibitors and can be used as medicaments for the therapeutic and/or prophylactic treatment of diseases such as diabetes, particularly type 2 diabetes, and other metabolic disorders.